ht1197 g4 Search Results


ht1197 g4  (ATCC)
95
ATCC ht1197 g4
Amiodarone decreases proliferation in bladder cancer cell lines. Real-time proliferation assays in UMUC3, <t>HT1197,</t> BFTC905, and RT112 were conducted using the Incucyte S3 system. The cells were treated with increasing concentrations of amiodarone (0–50 μmol/L), and the confluence was measured every 4 hours over 96 hours. A, Cell confluence over time. B, Cell confluence after 96 hours of treatment. Data represent mean ± SEM from at least three independent experiments (one-way ANOVA with Dunnett’s multiple comparisons test; *, P < 0.05; ***, P < 0.001; ****, P < 0.0001). C, Concentration–response curves and IC 50 values for amiodarone after 96 hours of treatment.
Ht1197 G4, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ht1197+g4/HT-1197/pmc12134865-54-8-11
Average 95 stars, based on 1 article reviews
ht1197 g4 - by Bioz Stars, 2026-09
95/100 stars
  Buy from Supplier

Image Search Results


Amiodarone decreases proliferation in bladder cancer cell lines. Real-time proliferation assays in UMUC3, HT1197, BFTC905, and RT112 were conducted using the Incucyte S3 system. The cells were treated with increasing concentrations of amiodarone (0–50 μmol/L), and the confluence was measured every 4 hours over 96 hours. A, Cell confluence over time. B, Cell confluence after 96 hours of treatment. Data represent mean ± SEM from at least three independent experiments (one-way ANOVA with Dunnett’s multiple comparisons test; *, P < 0.05; ***, P < 0.001; ****, P < 0.0001). C, Concentration–response curves and IC 50 values for amiodarone after 96 hours of treatment.

Journal: Cancer Research Communications

Article Title: Repurposing Amiodarone for Bladder Cancer Treatment

doi: 10.1158/2767-9764.CRC-24-0433

Figure Lengend Snippet: Amiodarone decreases proliferation in bladder cancer cell lines. Real-time proliferation assays in UMUC3, HT1197, BFTC905, and RT112 were conducted using the Incucyte S3 system. The cells were treated with increasing concentrations of amiodarone (0–50 μmol/L), and the confluence was measured every 4 hours over 96 hours. A, Cell confluence over time. B, Cell confluence after 96 hours of treatment. Data represent mean ± SEM from at least three independent experiments (one-way ANOVA with Dunnett’s multiple comparisons test; *, P < 0.05; ***, P < 0.001; ****, P < 0.0001). C, Concentration–response curves and IC 50 values for amiodarone after 96 hours of treatment.

Article Snippet: UMUC3 (basal mesenchymal phenotype) was obtained from Sigma-Aldrich, HT1197 (G4) from ATCC (CRL1473), and BFTC905 (G3) and RT112 (G2) from the German Collection of Microorganisms and Cell Cultures GmbH.

Techniques: Concentration Assay

Amiodarone induces apoptosis in bladder cancer cell lines. Cells were treated for 48 or 72 hours with amiodarone (0, 25, and 50 μmol/L for UMUC3; 0, 12.5, and 25 μmol/L for HT1197, BFTC905, and RT112). A, Apoptosis was evaluated using the Caspase-Glo 3/7 Assay and viability using the CellTiter cell proliferation assay. Apoptosis results were normalized to viability. Data are presented as apoptosis related to the control and represent mean ± SEM from at least three independent experiments (one-way ANOVA with Dunnett’s multiple comparisons test; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001). B, Western blot analysis of cPARP expression after 48 hours of treatment with 0, 12.5, and 25 μmol/L amiodarone. GAPDH was used as a loading control. Blots are representative of three independent experiments. Quantification of cPARP expression (normalized by GAPDH) is indicated under each corresponding band. Values are presented as expression related to the control.

Journal: Cancer Research Communications

Article Title: Repurposing Amiodarone for Bladder Cancer Treatment

doi: 10.1158/2767-9764.CRC-24-0433

Figure Lengend Snippet: Amiodarone induces apoptosis in bladder cancer cell lines. Cells were treated for 48 or 72 hours with amiodarone (0, 25, and 50 μmol/L for UMUC3; 0, 12.5, and 25 μmol/L for HT1197, BFTC905, and RT112). A, Apoptosis was evaluated using the Caspase-Glo 3/7 Assay and viability using the CellTiter cell proliferation assay. Apoptosis results were normalized to viability. Data are presented as apoptosis related to the control and represent mean ± SEM from at least three independent experiments (one-way ANOVA with Dunnett’s multiple comparisons test; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001). B, Western blot analysis of cPARP expression after 48 hours of treatment with 0, 12.5, and 25 μmol/L amiodarone. GAPDH was used as a loading control. Blots are representative of three independent experiments. Quantification of cPARP expression (normalized by GAPDH) is indicated under each corresponding band. Values are presented as expression related to the control.

Article Snippet: UMUC3 (basal mesenchymal phenotype) was obtained from Sigma-Aldrich, HT1197 (G4) from ATCC (CRL1473), and BFTC905 (G3) and RT112 (G2) from the German Collection of Microorganisms and Cell Cultures GmbH.

Techniques: Caspase-Glo Assay, Proliferation Assay, Control, Western Blot, Expressing